Beacon Pharmaceuticals PLC (DSE:BEACONPHAR)

Market Cap	24.26B
Revenue (ttm)	11.58B
Net Income (ttm)	570.05M
Shares Out	231.00M
EPS (ttm)	2.47
PE Ratio	42.55
Forward PE	n/a
Dividend	2.10 (2.00%)
Ex-Dividend Date	Nov 17, 2025

Volume	127,293
Average Volume	183,870
Open	105.60
Previous Close	105.80
Day's Range	104.70 - 106.50
52-Week Range	92.40 - 147.50
Beta	-0.54
RSI	42.98
Earnings Date	Nov 30, 2025

About Beacon Pharmaceuticals

Beacon Pharmaceuticals PLC engages in the producing and promoting of pharmaceuticals finished formulations, lifesaving intravenous fluids, active pharmaceutical ingredients, bio-tech products, and genetic engineering products in Bangladesh and internationally. The company offers general, oncology, biotech, and chronic care products. It also provides products in various therapeutic categories that include oncology, hematology, hepatology, nephrology, antibiotics, analgesics, anti-diabetics, respiratory, cardiovascular, dermatology, gastrointesti...

• Industry: Pharmaceutical Preparations
• Founded: 2001
• Employees: 4,162
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: BEACONPHAR

Financial Performance

In 2024, Beacon Pharmaceuticals's revenue was 10.70 billion, an increase of 25.76% compared to the previous year's 8.51 billion. Earnings were 521.01 million, an increase of 2.19%.